Inactive Instrument

Diplomat Pharmacy, Inc.

DPLO

Diplomat Pharmacy, Inc. Announces Executive Changes, Effective June 4,2018

May 15, 2018 at 04:51 pm EDT

Diplomat Pharmacy, Inc. announced that Mr. Wolin resigned as Chairman of the Board and was appointed independent Lead Director of the Board effective June 4,2018.

Latest news about Diplomat Pharmacy, Inc.

Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P 600 Health Care	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P 1000	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P 600	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P Composite 1500	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P 600 Health Care Services (Sub Ind)	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P TMI Index	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P Global BMI Index	20-02-13	CI
OptumRx, Inc. completed the acquisition of Diplomat Pharmacy, Inc. from Hagerman and others.	20-02-06	CI
Walgreen Co. acquired Certain Records of Diplomat Pharmacy, Inc. for $0.5 million.	19-12-22	CI
OptumRx, Inc. entered into an agreement to acquire Diplomat Pharmacy, Inc. from Hagerman and others for approximately $320 million.	19-12-08	CI
Transcript : Diplomat Pharmacy, Inc., Q3 2019 Earnings Call, Nov 12, 2019	19-11-12
Diplomat Pharmacy, Inc. Revises Earnings Guidance for the Full-Year 2019; Reports Impairments for the Third Quarter Ended September 30, 2019	19-11-12	CI
Diplomat Pharmacy, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Diplomat Pharmacy Continues to Pursue Comprehensive Strategic Alternatives Process	19-11-12	CI
Diplomat Pharmacy, Inc. Announces Executive Changes	19-10-02	CI
Transcript : Diplomat Pharmacy, Inc., Q2 2019 Earnings Call, Aug 09, 2019	19-08-09
Diplomat Pharmacy, Inc. Revises Earnings Guidance for the Full Year of 2019	19-08-09	CI
Diplomat Pharmacy, Inc. Reports Goodwill Impairments for the Second Quarter Ended June 30, 2019	19-08-09	CI
Diplomat Pharmacy, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-09	CI
Diplomat Announces Review Of Strategic Alternatives	19-08-09	CI
Diplomat Pharmacy, Inc. Signs Exclusive Practice-Based Infusion Agreement with Allergy Partners	19-08-08	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P Health Care Services Select Industry Index	19-06-24	CI
Transcript : Diplomat Pharmacy, Inc., Q1 2019 Earnings Call, May 07, 2019	19-05-07
Diplomat Pharmacy, Inc. Provides Earnings Guidance for the Full Year of 2019	19-05-07	CI
Diplomat Pharmacy, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-07	CI

Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company's patient care system is used to coordinate and track patient adherence and safety.

Sector

Drug Retailers

More about the company

Sector Other Drug Retailers

	1st Jan change	Capi.
WALGREENS BOOTS ALLIANCE, INC.	-41.10%	13.27B
JD HEALTH INTERNATIONAL INC.	-29.54%	11.76B
YIFENG PHARMACY CHAIN CO., LTD.	+14.31%	6.38B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-16.51%	6.96B
MATSUKIYOCOCOKARA & CO.	-13.56%	5.88B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+72.00%	4.98B
NAHDI MEDICAL COMPANY	-3.36%	4.59B
CLICKS GROUP LIMITED	-6.07%	3.98B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-18.47%	3.19B

Other Drug Retailers